Together, our observations suggest that the oncogenic activity of TAZ in this setting, and presumably also in human breast cancer, relies at least in part on its ability to modulate the immune TME and suppress anti‐tumour immunity, thereby augmenting cancer cell survival and favouring tumour progression. This evidence concerns the gene WWTR1 and neoplasm.